India Pharma Outlook Team | Thursday, 18 June 2026
Lupin enters hypertension drug market as it announced the commercial launch of Azilsartan Medoxomil tablets in the United States.
The launch marks an important addition to Lupin’s cardiovascular portfolio and comes after the company received final approval from the US Food and Drug Administration (USFDA) for the generic version of Takeda’s Edarbi tablets.
With an estimated annual market size of USD 101 million, the move is expected to strengthen Lupin’s position in the US generics market and support future revenue growth.
The USD 101 million US market opportunity is particularly attractive as Azilsartan Medoxomil is used to treat hypertension, a chronic condition that requires long-term medication. The product is available in 40 mg and 80 mg strengths and is expected to expand Lupin’s presence in the cardiovascular segment, one of the largest therapy areas in the US pharmaceutical market.
The newly launched Azilsartan Medoxomil tablets are the generic equivalent of Takeda’s Edarbi, a widely prescribed medication used to manage high blood pressure. The commercial rollout follows the company’s successful transition from regulatory approval to market availability in the US.
According to IQVIA MAT data for March 2024, the reference market for the drug generated estimated annual sales of approximately USD 101 million in the United States. By entering this segment, Lupin gains access to a sizeable market while strengthening its portfolio of cardiovascular products.
Also Read: Digital Health & E-Pharmacy: Reimagining Access, Trust & Care
The launch aligns with Lupin’s strategy of focusing on high-value and niche generic products in regulated markets. Indian pharmaceutical companies have increasingly shifted toward complex generics and specialty medicines to reduce dependence on highly competitive commodity products.
Azilsartan Medoxomil fits into this approach by offering exposure to a chronic therapy category with stable demand. Such launches typically provide better margin potential, especially when competition remains limited during the initial phase after commercialization.
The development also improves visibility for Lupin’s complex generics pipeline in the US market. The company has been investing heavily in research and development to strengthen its portfolio and maintain a steady stream of differentiated product launches.
The launch is expected to be margin-accretive for Lupin’s US business and could support continued growth in North America. Revenue visibility improves as the company enters a market with consistent demand driven by long-term treatment needs.
The broader pharmaceutical industry is witnessing a similar trend, with Indian drugmakers focusing on specialty products and complex generics to counter years of pricing pressure in the US generics market. Cardiovascular therapies continue to be among the most reliable volume drivers due to the high prevalence of hypertension and related disorders.
Investors will closely monitor several factors in the coming quarters, including:
Lupin recently reported a significant increase in consolidated net profit to Rs 359 crore in Q4 FY24, supported by strong performance in both the US and Indian markets. The company also completed the divestment of its South African subsidiary, Multicare, as part of its strategy to focus on core growth markets.
The successful commercialization of Azilsartan Medoxomil highlights Lupin’s continued execution in the US market and reinforces its focus on building a portfolio of higher-value products capable of supporting long-term growth.
Lupin Limited is one of India’s leading pharmaceutical companies with operations across more than 100 countries. The company develops and manufactures branded and generic formulations, biotechnology products, and active pharmaceutical ingredients.
.jpg)
